Shield Therapeutics plc (STX.L)
STX.L Stock Price Chart
Explore Shield Therapeutics plc interactive price chart. Choose custom timeframes to analyze STX.L price movements and trends.
STX.L Company Profile
Discover essential business fundamentals and corporate details for Shield Therapeutics plc (STX.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
26 Feb 2016
Employees
63.00
CEO
Anders Lundstrom
Description
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
STX.L Financial Timeline
Browse a chronological timeline of Shield Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 2 Sept 2025
Earnings released on 28 Apr 2025
Earnings released on 24 Apr 2025
EPS came in at -£0.01 surpassing the estimated -£0.01 by +19.90%, while revenue for the quarter reached £15.53M, missing expectations by -3.14%.
Earnings released on 4 Sept 2024
EPS came in at -£0.02, while revenue for the quarter reached £9.59M.
Earnings released on 30 Apr 2024
Earnings released on 25 Apr 2024
EPS came in at -£0.02, while revenue for the quarter reached £6.98M.
Earnings released on 28 Sept 2023
EPS came in at -£0.01, while revenue for the quarter reached £3.51M.
Earnings released on 28 Jun 2023
Earnings released on 27 Apr 2023
EPS came in at -£0.11, while revenue for the quarter reached £2.44M.
Stock split effective on 16 Dec 2022
Shares were split 1029:1000, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Sept 2022
EPS came in at -£0.05, while revenue for the quarter reached £2.03M.
Earnings released on 30 Jun 2022
Earnings released on 31 Dec 2021
EPS came in at -£0.05, while revenue for the quarter reached £1.04M.
Earnings released on 30 Jun 2021
EPS came in at -£0.04, while revenue for the quarter reached £481.00K.
Stock split effective on 1 Mar 2021
Shares were split 1029:1000, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2020
EPS came in at -£0.05, while revenue for the quarter reached £1.47M.
Earnings released on 16 Sept 2020
EPS came in at £0.03, while revenue for the quarter reached £9.39M.
STX.L Stock Performance
Access detailed STX.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.